Find out more about the work we have been doing by watching our presentations given at the annual UK CFS/ME Research Collaborative Conference (CMRC) in Bristol and selected conferences.

CMRC 2017 - Prof James McCullagh

CMRC 2017 - Dr Karl Morten

New Zealand 2018 - Dr Karl Morten

CMRC 2020 - Dr Karl Morten

CMRC 2020 - Megan Stoker

Find out more about the work we have published below.

Potter, M., Newport, E., & Morten, K. J. (2016). The Warburg effect: 80 years on. Biochemical Society Transactions, 44(5), 1499–1505. https://doi.org/10.1042/BST20160094

Diot, A., Agnew, T., Sanderson, J., Liao, C., Carver, J., Neves, R., Gupta, R., Guo, Y., Waters, C., Seto, S., Daniels, M. J., Dombi, E., Lodge, T., Morten, K., Williams, S. A., Enver, T., Iborra, F. J., Votruba, M., & Poulton, J. (2018). Validating the RedMIT/GFP-LC3 Mouse Model by Studying Mitophagy in Autosomal Dominant Optic Atrophy Due to the OPA1Q285STOP Mutation. Frontiers in cell and developmental biology, 6, 103. https://doi.org/10.3389/fcell.2018.00103

Stoker, M. L., Newport, E., Hulit, J. C., West, A. P., & Morten, K. J. (2019). Impact of pharmacological agents on mitochondrial function: a growing opportunity?. Biochemical Society Transactions, 47(6), 1757–1772. https://doi.org/10.1042/BST20190280

Tomas, C., Lodge, T. A., Potter, M., Elson, J. L., Newton, J. L., & Morten, K. J. (2019). Assessing cellular energy dysfunction in CFS/ME using a commercially available laboratory test. Scientific Reports, 9(1), 11464. https://doi.org/10.1038/s41598-019-47966-z

Xu J , Potter M , Tomas C , et al. A new approach to find biomarkers in chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) by single-cell Raman micro-spectroscopy [published correction appears in Analyst. 2019 Jul 7;144(13):4121]. Analyst. 2019;144(3):913‐920. https://doi:10.1039/c8an01437j

***PLEASE SEE BELOW: Zalewski, P., Kujawski, S., Tudorowska, M., Morten, K., Tafil-Klawe, M., Klawe, J. J., Strong, J., Estévez-López, F., Murovska, M., Newton, J. L., & The European Network On Me/Cfs Euromene (2019). The Impact of a Structured Exercise Programme upon Cognitive Function in Chronic Fatigue Syndrome Patients. Brain Sciences, 10(1), 4. https://doi.org/10.3390/brainsci10010004

In view of transparency of our previous work, we have included this paper***. The Morten Group DOES NOT ENDORSE GET (graded exercise therapy). Please have a look at these resources demonstrating GET to be detrimental to patients with ME/CFS. The CDC has also removed its recommendations for GET and CBT (cognitive behavioural therapy) for ME/CFS from their website in 2017.

• Wilshire, C.E., Kindlon, T., Courtney, R. et al (2018). Rethinking the treatment of chronic fatigue syndrome—a reanalysis and evaluation of findings from a recent major trial of graded exercise and CBT. BMC Psychol 6, 6. https://doi.org/10.1186/s40359-018-0218-3
• Vink, M., & Vink-Niese, A. (2018). Graded exercise therapy for myalgic encephalomyelitis/chronic fatigue syndrome is not effective and unsafe. Re-analysis of a Cochrane review. Health Psychology Open. https://doi.org/10.1177/2055102918805187​
• Geraghty, K., Hann, M., & Kurtev, S. (2019). Myalgic encephalomyelitis/chronic fatigue syndrome patients’ reports of symptom changes following cognitive behavioural therapy, graded exercise therapy and pacing treatments: Analysis of a primary survey compared with secondary surveys. Journal of Health Psychology, 24(10), 1318–1333. https://doi.org/10.1177/1359105317726152
• BMJ Blog—Commentary by Michiel Tack (2019): Why Graded Exercise Therapy and Cognitive Behaviour Therapy are Controversial in Chronic Fatigue Syndrome
• Action For ME UK: Link on GET and CBT for ME/CFS.
• ME Action: GET and CBT are not safe for ME

NB: The importance of studying Post Exertional Malaise (PEM) or the deleterious response to GET should not be underestimated. Although we are not advocating running new GET studies we will be publishing our results showing the impact of GET (essentially an inducer of PEM – the cardinal symptom of ME/CFS) on metabolic profiles and biological/clinical variables in ME/CFS. Our preliminary findings showed that there are no changes between the metabolic profiles of patients with ME/CFS post-GET and prior to GET. These preliminary results (Strong et al., 2019) have been presented at the 2019 MitOx Conference and the 2019 Oxford Metabolic Health Symposium. A working paper is in progress.